Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20377294 | 0.90 | ESR2 (0.36) | MEN1LMNABLMHBBKMT2A | |
| SCHEMBL457977 | 0.83 | — | — | |
| SCHEMBL20377293 | 0.82 | TSHR (0.33) | ESR1 | |
| Methane SCHEMBL2013838 | 0.81 | LMNA (0.46) | MEN1LMNABLMHBBKMT2A | |
| Ethane SCHEMBL2012063 | 0.79 | LMNA (0.44) | MEN1LMNABLMHBBKMT2A | |
| SCHEMBL20486280 | 0.72 | BCL9 (0.34) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL2232094 | 0.72 | BLM (0.41) | MEN1LMNABLMHBBKMT2A | |
| SCHEMBL397067 | 0.72 | BLM (0.41) | MEN1LMNABLMHBBKMT2A | |
| SCHEMBL457635 | 0.71 | LMNA (0.44) | MEN1LMNABLMHBBKMT2A | |
| Adipic Acid SCHEMBL31124541 | 0.71 | LMNA (0.55) | MEN1LMNABLMKMT2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349911-B | Nitric oxide releasing prodrug molecules | 浙江华海药业股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-10-29 | — | — | US | disclosed |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | PTGIS, NOS1, NOS2 | MEN1 3887/4885LMNA 2346/4885BLM 4276/4885 |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | NOS1, NOS2, PTGIS | MEN1 3406/4885LMNA 1662/4885BLM 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.